Partnerships & Licensing
License agreement with Kansas State University Research Foundation (KSURF) to further develop certain proprietary broad-spectrum compounds for coronavirus and norovirus.
InterX Inc. and HitGen Collaboration
Research collaboration with InterX, Inc., a private Silicon Valley computer software company, and HitGen, Ltd., a public biotechnology company (SHSE: Shanghai Stock Exchange), to develop small molecule drug candidates against several undisclosed targets.
We are always looking at opportunities to create value through partnering opportunities.
Learn more about Partnership & Licensing opportunities.